Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Executive Summary

• Appili Therapeutics closed the first tranche of its non‑brokered private placement, raising C$177,500 from the sale of 7.1 million units at C$0.025 per unit.
• Each unit includes one Class A common share and half of a common‑share purchase warrant (exercise price C$0.05, exercisable for 36 months pending shareholder approval).
• Net proceeds will be used primarily for working capital and to fund development of the company’s product candidates; a second tranche is planned for December 2025.

Key Details

• Units sold: 7,100,000 units at C$0.025 per unit → Gross proceeds: C$177,500.
• Unit composition: 1 Class A common share + ½ Common Share purchase warrant.
• Warrant terms: One whole warrant (per two units) gives the holder the right to buy one common share at C$0.05 per share; exercisable for 36 months after closing, subject to shareholder approval at the next AGM.
• Finder fees paid: C$14,200.
• Broker warrants issued: 568,000 broker warrants; each allows purchase of one common share at a price not less than C$0.02834 per share for 24 months after closing, also subject to shareholder approval at the next AGM.
• Use of proceeds: Primarily working capital and funding development of selected product candidates.
• Future financing: A secondary tranche of the private placement is slated for closure in December 2025.
• Statutory hold period: All securities issued are subject to a four‑month‑plus‑one‑day hold period from issuance date.

Notable Quotes

(No executive quotes were included in the release.)